Prognostic analysis for treatment modalities in hepatocellular carcinomas with portal vein tumor thrombi

Asian Pac J Cancer Prev. 2011;12(11):2847-50.

Abstract

Objective: To assess prognostic aspects of treatment modalities for cases of hepatocellular carcinoma (HCC) with portal vein tumor thrombi (PVTT).

Method: 121 treated cases were retrospectively divided into five groups: 1 (liver transplantation); 2 (transcatheter arterial chemoembolization); 3 (hepatectomy plus thrombectomy); 4 (hepatectomy plus thrombectomy combined with adjuvant chemobiotherapy via portal vein); and 5 (conservative treatment). The Kaplan-Meier method with difference in survival estimated by Log-rank test was used to compare between groups.

Result: Groups 1-5 had a significantly differing median survival times of 7, 7, 10, 16, 3 months (P<0.05), respectively. One- and three-year survival rates were 30.0% and 10.0%, 20.0% and 0.0%, 47.0% and 22.0%, 70% and 20%, and 12% and 4%.

Conclusion: Surgical resection combined with adjuvant chemotherapy via the portal vein is an effective and safe treatment modality for hepatocellular carcinoma with portal vein tumor thrombi.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Carcinoma, Hepatocellular / drug therapy
  • Carcinoma, Hepatocellular / pathology
  • Carcinoma, Hepatocellular / surgery
  • Carcinoma, Hepatocellular / therapy*
  • Chemoembolization, Therapeutic
  • Chemotherapy, Adjuvant
  • Child
  • Combined Modality Therapy
  • Female
  • Hepatectomy
  • Humans
  • Liver Neoplasms / drug therapy
  • Liver Neoplasms / pathology
  • Liver Neoplasms / surgery
  • Liver Neoplasms / therapy*
  • Liver Transplantation
  • Male
  • Middle Aged
  • Portal Vein / pathology
  • Portal Vein / surgery*
  • Survival Rate
  • Thrombectomy
  • Venous Thrombosis / pathology
  • Venous Thrombosis / surgery
  • Venous Thrombosis / therapy*
  • Young Adult